IL136163A0 - Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection - Google Patents

Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection

Info

Publication number
IL136163A0
IL136163A0 IL13616398A IL13616398A IL136163A0 IL 136163 A0 IL136163 A0 IL 136163A0 IL 13616398 A IL13616398 A IL 13616398A IL 13616398 A IL13616398 A IL 13616398A IL 136163 A0 IL136163 A0 IL 136163A0
Authority
IL
Israel
Prior art keywords
preventing
effects related
retroviral infection
pathogenic effects
obtaining vaccines
Prior art date
Application number
IL13616398A
Other languages
English (en)
Original Assignee
Hippocampe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hippocampe filed Critical Hippocampe
Publication of IL136163A0 publication Critical patent/IL136163A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL13616398A 1997-11-17 1998-11-17 Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection IL136163A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714387A FR2771011B1 (fr) 1997-11-17 1997-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
PCT/FR1998/002447 WO1999025377A1 (fr) 1997-11-17 1998-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Publications (1)

Publication Number Publication Date
IL136163A0 true IL136163A0 (en) 2001-05-20

Family

ID=9513450

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13616398A IL136163A0 (en) 1997-11-17 1998-11-17 Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection
IL136163A IL136163A (en) 1997-11-17 2000-05-16 Method for receiving a vaccine to prevent pathogenic effects associated with retroviral infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL136163A IL136163A (en) 1997-11-17 2000-05-16 Method for receiving a vaccine to prevent pathogenic effects associated with retroviral infection

Country Status (19)

Country Link
US (3) US6455265B1 (da)
EP (1) EP1034000B1 (da)
JP (1) JP4837823B2 (da)
KR (1) KR20010032210A (da)
CN (1) CN1281371A (da)
AP (1) AP2000001841A0 (da)
AT (1) ATE353017T1 (da)
AU (1) AU1243499A (da)
BR (1) BR9814204A (da)
CA (1) CA2309676C (da)
DE (1) DE69837012T2 (da)
DK (1) DK1034000T3 (da)
EA (1) EA200000528A1 (da)
ES (1) ES2281938T3 (da)
FR (1) FR2771011B1 (da)
IL (2) IL136163A0 (da)
OA (1) OA11522A (da)
PT (1) PT1034000E (da)
WO (1) WO1999025377A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
CN1396178A (zh) * 2002-06-17 2003-02-12 成都阳辉生物科技有限责任公司 抗乙肝病毒等包膜病毒感染的工程多肽及其制备方法
ATE508139T1 (de) 2003-04-11 2011-05-15 Pasteur Institut Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper
EP1680444A1 (en) * 2003-07-30 2006-07-19 Mymetics Corporation New soluble and stabilized trimeric form of gp41 polypeptides
JP2007505320A (ja) * 2003-09-11 2007-03-08 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスの検出のための方法と装置
AU2004304348B2 (en) * 2003-12-18 2009-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
CA2556141A1 (en) * 2004-02-19 2005-09-01 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP1732585B1 (en) * 2004-03-30 2010-06-30 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
EP1761556A1 (en) * 2004-06-30 2007-03-14 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
EP1761564A1 (en) * 2004-06-30 2007-03-14 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP4307505B2 (ja) * 2004-06-30 2009-08-05 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスの検出のための方法と装置
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP5020941B2 (ja) * 2005-05-02 2012-09-05 マイメティクス コーポレーション Ｈｉｖに対して中和活性を有するがｉｌ２には中和活性を有さない抗体又はその断片
TWI343180B (en) * 2005-07-01 2011-06-01 Ind Tech Res Inst The acoustic wave sensing-device integrated with micro channels
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN1869704B (zh) * 2006-06-14 2010-06-30 厦门大学 快速鉴定与病原菌互作的宿主蛋白的方法
WO2010042760A2 (en) * 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
AU2010210073B2 (en) 2009-02-06 2016-06-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Splitting gp41
US8765137B2 (en) 2009-02-06 2014-07-01 Mymetics Corporation Gp41 antigens
WO2011022725A2 (en) * 2009-08-21 2011-02-24 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
EP2553452B1 (en) 2010-04-02 2015-03-04 IDEXX Laboratories, Inc. Detection of feline immunodeficiency virus
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2013308623B2 (en) 2012-08-30 2017-03-02 Merial, Inc. Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CN111701016A (zh) * 2020-06-28 2020-09-25 张全志 逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001304A1 (en) * 1991-07-10 1993-01-21 Synbiotics Corporation Synthetic peptides related to fiv-env proteins
CA2140663C (en) * 1992-07-20 2004-01-27 Carl T. Wild Compounds which inhibit hiv replication
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Also Published As

Publication number Publication date
US7829683B2 (en) 2010-11-09
EP1034000A1 (fr) 2000-09-13
CA2309676C (fr) 2012-08-07
FR2771011A1 (fr) 1999-05-21
WO1999025377A1 (fr) 1999-05-27
EP1034000B1 (fr) 2007-01-31
ES2281938T3 (es) 2007-10-01
CN1281371A (zh) 2001-01-24
AP2000001841A0 (en) 2000-06-30
DK1034000T3 (da) 2007-06-04
OA11522A (fr) 2004-02-09
FR2771011B1 (fr) 2000-01-28
ATE353017T1 (de) 2007-02-15
DE69837012D1 (de) 2007-03-22
KR20010032210A (ko) 2001-04-16
CA2309676A1 (fr) 1999-05-27
BR9814204A (pt) 2000-10-03
EA200000528A1 (ru) 2001-02-26
IL136163A (en) 2007-07-04
US7253270B2 (en) 2007-08-07
JP2001524456A (ja) 2001-12-04
US20080003229A1 (en) 2008-01-03
US6455265B1 (en) 2002-09-24
US20040014046A1 (en) 2004-01-22
US20050048478A9 (en) 2005-03-03
AU1243499A (en) 1999-06-07
DE69837012T2 (de) 2007-11-29
PT1034000E (pt) 2007-05-31
JP4837823B2 (ja) 2011-12-14

Similar Documents

Publication Publication Date Title
IL136163A0 (en) Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
IL136447A0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
GB9812613D0 (en) Vaccine
HK1028619A1 (en) Process for the preparation of a polyamide-polyurethane micro-blend
HUP0104842A3 (en) Vaccine
ZA957482B (en) Vaccine
TJ307B (en) A method for the preparation of a anti - theileriosis vaccine
ITMI942056A0 (it) Procedimento per la preparazione di un tiazolinoazetidinone
GB9807805D0 (en) Vaccine
GB9821821D0 (en) Schistomiasis vaccine
GB9820956D0 (en) Vaccine
TJ97000483A (en) A method for the preparation of an anti - theileriosis vaccine
GB9412521D0 (en) Vaccine production
GB9412470D0 (en) Vaccine
GB9423928D0 (en) Vaccine
IL121253A0 (en) A process for the preparation of para-fluorophenol
GB9718902D0 (en) Vaccine
GB9720982D0 (en) Vaccine
GB9717423D0 (en) Vaccine
GB9405925D0 (en) Vaccines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed